SLS

SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

SELLAS Life Sciences Group, Inc. (SLS) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Profitability (C-). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
B
Factor Score 3.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -39.3
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -39.5%
Price Return 12M 427.5%
Catalyst Signal 0.00
Market Cap $1.6B
TTM Revenue N/A
Price / Sales N/A
ROE -40.3%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) C+ (2.7) C- (2.0) B (3.3) C+ (2.6) C+ (2.6)
2026-11-07 C+ (2.5) C+ (2.8) D (1.4) B (3.4) C+ (2.7) C+ (2.5)
2026-10-31 C+ (2.5) C+ (2.7) D (1.4) B (3.4) C+ (2.7) C+ (2.5)
2026-10-24 C+ (2.5) C+ (2.7) D (1.4) B (3.4) C+ (2.6) C+ (2.5)
2026-10-17 C+ (2.5) C+ (2.7) D (1.4) B (3.4) C+ (2.6) C+ (2.5)
Page 1 of 4